Institution
Eastern Cooperative Oncology Group
Facility•Philadelphia, Pennsylvania, United States•
About: Eastern Cooperative Oncology Group is a facility organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 249 authors who have published 170 publications receiving 26514 citations. The organization is also known as: ECOG.
Topics: Cancer, Breast cancer, Chemotherapy, Leukemia, Hazard ratio
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The toxicity was qualitatively and quantitatively similar to that reported with other bleomycin doses, schedules and routes of administration except that no radiographic evidence of pulmonary toxicity was seen.
3 citations
••
3 citations
••
TL;DR: Efforts are ongoing to further classify solid tumors by immunoscores, which have prognostic implications and may also have predictive value and identify targets for novel therapies to increase cure rates.
Abstract: Meeting abstracts
Efforts are ongoing to further classify solid tumors by immunoscores, which have prognostic implications and may also have predictive value and identify targets for novel therapies to increase cure rates. TNBC are highly aggressive breast cancers, which are frequently infiltrated
3 citations
••
TL;DR: Higher expression of GRB7 RNA expression is associated with a significantly higher risk of recurrence in triple-negative breast cancer, indicating that GRB 7 orGRB7 -dependent pathways are potential therapeutic targets in double-negative disease.
Abstract: CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts
Abstract #25
Background: Breast cancer lacking expression of the estrogen and progesterone receptor and overexpression of HER2/ neu (ie, "triple-negative” disease) accounts for about 10-15% of all breast cancer and is characterized by a higher risk of recurrence, early recurrence, resistance to cytotoxic therapy, and lack of any specific targeted therapy. Methods: We extracted RNA from primary tumor samples of 246 patients with stage I-III triple-negative breast cancer (confirmed in a central lab) treated with 4 cycles of adjuvant doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) or docetaxel (60 mg/m2) who were enrolled on trial E2197, and correlated RNA expression (by quantitative RT-PCR using a panel of 371 rationally selected genes) with recurrence. There was no difference in recurrence between the two treatment arms in the entire study population, nor in the 246 patients in this analysis (of whom 59 recurred) after a median followup of 76 months. Results: Higher expression of GRB7 was the only gene significantly associated with an increased risk of recurrence (nominal p value 0.0000853, Korn's adjusted p value controlling false discovery at 10% (KP10) p=0.0359), but did not correlate with any clinicopathologic features except age (low expression associated with age > 65 years, p=0.03). In a Cox proportional hazards model adjusted for age, nodal status, tumor size, and grade, higher GRB7 expression was associated with an increased risk of recurrence when evaluated as a continuous variable (hazard ratio 3.41; p = 0.001) or as a dichotomous variable (hazard ratio 2.24 above vs. below median; p=0.006). The 5-year recurrence rates were 10.5% (95% C.I.7.8%, 14.1%) in the low and 20.4% (95% C.I. 16.5%, 25.0%) in the high GRB7 groups. There were only six genes whose expression correlated with GRB7 (r> 0.4), including ERBB2 (r=0.70), DDR1 (discoidin domain receptor tyrosine kinase 1; r=0.53), KRT19 (keratin 19; r=0.49), ERBB3 (r=0.48), GPR56 (G protein-coupled receptor 56; r=0.48) and PHB (prohibitin; r=0.42). Conclusions: GRB7 is a calmodulin-binding protein which has an SH2 (Src homology 2) domain that binds to phosphorylated tyrosine residues and other specific protein targets, and which plays a critical role in signaling (EGFR, HER2), motility (eprhins), migration (focal adhesion kinase), and cell-matrix/cell-cell interactions (integrins). Higher GRB7 RNA expression is associated with a significantly higher risk of recurrence in triple-negative breast cancer, indicating that GRB7 or GRB7 -dependent pathways are potential therapeutic targets in triple-negative disease.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 25.
3 citations
••
TL;DR: Results show that response rate, the role of maintenance and reinduction in a cohort of patients with high-risk MM, and the 1- and 2-year OS rates were 88.1% ( 95%CI 73.7–94.9%) and 76.7% (95%CI 58.8–87.4%) respectively.
3 citations
Authors
Showing all 249 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Cella | 156 | 1258 | 106402 |
Donna Neuberg | 135 | 810 | 72653 |
Stanley R. Hamilton | 126 | 441 | 94831 |
Martin S. Tallman | 117 | 917 | 60011 |
Al B. Benson | 113 | 578 | 48364 |
Richard Gray | 109 | 808 | 78580 |
David H. Johnson | 103 | 488 | 55925 |
Nancy E. Davidson | 99 | 384 | 63544 |
Michael A. Carducci | 91 | 574 | 39457 |
George P. Canellos | 88 | 343 | 32151 |
Hillard M. Lazarus | 88 | 575 | 31572 |
John M. Bennett | 88 | 458 | 54128 |
Antonio C. Wolff | 82 | 378 | 41408 |
Rebecca Gelman | 81 | 283 | 34736 |
Edward A. Stadtmauer | 81 | 427 | 28392 |